Eli Lilly, a major U.S.-based pharmaceutical company, has launched its blockbuster diabetes and weight-loss drug, Mounjaro (tirzepatide), in India after receiving approval from the country’s drug regulator. This marks a significant step for the company in tapping into the growing market in India, which is experiencing increasing rates of obesity and diabetes.
India, the world’s most populous country, has an estimated 101 million people living with diabetes, and obesity is a major risk factor for the disease. Eli Lilly’s Mounjaro offers a dual solution, addressing both obesity and type 2 diabetes, which are becoming major public health concerns in the country.
Mounjaro is already available in the UK and Europe for treating both diabetes and weight loss, and in the U.S., it is marketed under the name Zepbound for obesity. The drug has generated significant global demand due to its effectiveness, and analysts project that global obesity drug sales could reach $150 billion annually by the early 2030s.
With the approval and launch of Mounjaro in India, Eli Lilly is poised to capitalize on the rising demand for effective treatments for obesity and diabetes in one of the world’s largest markets.
Related Topics:
What Weight Loss Injections Are Covered By Insurance
